Our combination therapy is advantageous by targeting MDSCs expressing IDO and enhancing CD8+ T cell metabolism necessary to achieve anti-tumor immunity, thus potentially making it successful without the use of additional IDO inhibitors. The gene discussed is CD8A; the disease is neoplasm.